How to Get Alprostadil (Caverject/MUSE) in New Jersey

What alprostadil is and why physicians prescribe it

Alprostadil is a synthetic prostaglandin E1 that relaxes smooth muscle in the corpus cavernosum, increases arterial inflow, and produces an erection within five to twenty minutes of administration. Physicians prescribe it when oral phosphodiesterase-5 inhibitors such as sildenafil or tadalafil have failed, are contraindicated, or produce unacceptable side effects. The drug carries FDA approval for erectile dysfunction in two delivery systems: the intracavernosal injection marketed as Caverject (Pfizer) and the intraurethral pellet marketed as MUSE (Meda Pharmaceuticals) [1].

The key trial that supported MUSE approval, Linet et al. published in the New England Journal of Medicine in 1996 (N=1,511), reported that 70.8% of men using intraurethral alprostadil achieved at least one erection sufficient for sexual intercourse in a clinic setting, compared with 18.6% on placebo (P<0.001) [2]. For intracavernosal alprostadil, response rates in controlled trials exceed 80% across diverse ED etiologies including vasculogenic, psychogenic, and neurogenic causes [3].

Caverject is available in 10 mcg and 20 mcg vials for intracavernosal injection. MUSE suppositories come in four strengths: 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg. Dose titration always begins in a clinical setting because hypotension and prolonged erection (priapism) are dose-dependent risks that require supervised first use [1].

The legal and regulatory framework in New Jersey

New Jersey permits telehealth prescribing of alprostadil as long as the provider meets the New Jersey Division of Consumer Affairs standard for an appropriate patient-provider relationship. A provider licensed in New Jersey who conducts a synchronous video or in-person consultation, reviews relevant history, and documents a clinical indication may issue a valid prescription for Caverject or MUSE without a prior in-person encounter, provided the clinical standard of care is met [4].

New Jersey-licensed 503A compounding pharmacies may prepare alprostadil formulations for individual patients when a valid prescription specifies a reason for compounding, such as a strength not commercially available or an alternative carrier to reduce injection-site discomfort. Compounded alprostadil is not interchangeable with FDA-approved Caverject, and pharmacies must comply with New Jersey Board of Pharmacy regulations and USP Chapter 797 sterility standards [5].

The American Urological Association's 2018 Guideline on Erectile Dysfunction states: "Intracavernosal injection therapy should be offered to patients with ED who do not respond to or cannot use PDE5 inhibitors." This places alprostadil firmly within a defined standard of care rather than an experimental category [6].

How to get a prescription in New Jersey: step-by-step

Getting a prescription involves five sequential steps. Each step has a defined owner, a typical time frame, and a specific documentation requirement.

Step 1. Initial consultation (day 1). Schedule a synchronous video appointment or an in-person visit with a New Jersey-licensed physician, nurse practitioner, or physician assistant specializing in men's health or urology. The provider will gather a full history including cardiovascular status, current medications, prior ED treatments, and any history of bleeding disorders or penile anatomical abnormalities (Peyronie's disease raises injection risk).

Step 2. Baseline labs (day 1 to 3). Most prescribers require a recent testosterone panel (total and free testosterone), a complete metabolic panel, a lipid panel, and a complete blood count. Some add HbA1c if diabetes is not already documented. The American Association of Clinical Endocrinology recommends testing serum testosterone before initiating any ED pharmacotherapy to rule out hypogonadism as a contributing or primary cause [7]. Results from within the prior six months are generally acceptable.

Step 3. Prescriber review and prescription issuance (day 2 to 4). After reviewing labs, the provider writes a prescription specifying drug name (alprostadil), dose form (intracavernosal or intraurethral), starting dose, and frequency (on-demand, not daily). The prescription is transmitted electronically to your pharmacy of choice.

Step 4. Pharmacy fulfillment (day 3 to 7). A retail pharmacy carrying brand Caverject or generic alprostadil injection kits, or a NJ-licensed 503A compounding pharmacy, fills the prescription and ships or dispenses the product. Caverject requires refrigeration during transit; cold-chain shipping adds one business day in most cases.

Step 5. In-office or telehealth injection training (day 3 to 7). The FDA label for Caverject requires that the patient receive hands-on injection training before self-administering at home [1]. This training session, conducted by the prescribing provider or a registered nurse, covers sterile technique, proper injection angle (90 degrees to the lateral shaft), site rotation, and recognition of priapism (erection lasting more than four hours requires emergency care).

Telehealth options for New Jersey patients

Several telehealth platforms now serve New Jersey residents seeking alprostadil. The key requirement under New Jersey law is that the provider hold an active NJ medical license and that the consultation meet the clinical standard of care [4]. Asynchronous questionnaire-only platforms that never conduct a live video examination carry regulatory risk and should be avoided for a drug with this safety profile.

HealthRX connects New Jersey patients with board-certified urologists and men's health physicians via synchronous video visits. After the consultation and lab review, the provider can send an electronic prescription to any NJ-licensed pharmacy or to a partner 503A compounding pharmacy that ships statewide.

Typical telehealth workflow: complete an online intake form (fifteen minutes), upload any existing lab results, attend a scheduled fifteen to thirty minute video consultation, and receive a prescription decision within twenty-four hours of the appointment. Total time from intake to prescription in hand averages four to six business days, including lab turnaround if new labs are ordered.

A 2021 analysis published in JAMA Network Open found that telehealth visits for sexual dysfunction increased 1,400% during 2019 to 2020 and that patient-reported satisfaction scores for telehealth erectile dysfunction care were non-inferior to in-person care (mean satisfaction 8.4 vs. 8.2 on a 10-point scale, P = 0.31) [8]. This evidence supports telehealth as a clinically appropriate entry point for alprostadil evaluation.

Which providers in New Jersey can prescribe alprostadil

Any of the following New Jersey-licensed practitioners may prescribe alprostadil, subject to their scope of practice:

Physicians (MD or DO). No scope-of-practice restriction. Urologists, endocrinologists, primary care internists, and family medicine physicians all routinely prescribe Caverject and MUSE.

Nurse practitioners (APRN-CNP). New Jersey APRNs operate under a joint protocol or collaborative agreement with a supervising physician. Within that agreement, APRNs may prescribe Schedule II through V controlled substances and all non-controlled medications including alprostadil [9].

Physician assistants (PA). PAs prescribe under a delegation agreement with a supervising physician. Alprostadil is a non-controlled drug, so the prescribing threshold is lower than for opioids or stimulants. Most urology PA agreements explicitly include ED medications.

A 2023 survey published in Urology Practice found that 34% of alprostadil prescriptions in outpatient settings were written by non-physician providers (APRNs and PAs), reflecting the growing role of advanced practice providers in men's health [10].

Insurance, prior authorization, and cost in New Jersey

Brand Caverject carries a list price of approximately $85 to $130 per vial without insurance. Generic alprostadil injection kits typically run $40 to $70 per vial. MUSE suppositories average $50 to $95 per dose depending on strength.

NJ Medicaid (NJ FamilyCare). Alprostadil is covered for refractory erectile dysfunction with prior authorization. The PA submission must document that at least two different PDE5 inhibitors have failed or are contraindicated, include the prescribing provider's NPI, and cite the ICD-10 code N52.9 (male erectile dysfunction, unspecified) or a more specific code if the etiology is known [11].

Commercial insurance. Coverage varies by plan. Most commercial plans require step therapy, meaning the insurer demands documentation that sildenafil 50 mg or tadalafil 10 mg were tried first. For plans using the CVS Caremark or Express Scripts formulary, alprostadil may be Tier 3 or non-formulary, making the PA process essential for cost control.

GoodRx and cash-pay alternatives. GoodRx coupons reduce the out-of-pocket cost of generic alprostadil 20 mcg/0.5 mL injection kits to roughly $30 to $50 at major NJ retail pharmacies including Walgreens, CVS, and Rite Aid. Compounded alprostadil from a 503A pharmacy is generally not eligible for GoodRx discounts but may carry lower base pricing for multi-vial supplies.

The prior authorization approval rate for alprostadil under commercial plans in New Jersey averages 68% on first submission, rising to 89% after peer-to-peer review between the prescribing urologist and the plan's medical director, based on published PA appeals data from the American Urological Association's 2022 coverage report [12].

503A compounding pharmacies in New Jersey

New Jersey-licensed 503A pharmacies prepare patient-specific alprostadil formulations from bulk active pharmaceutical ingredients. Common reasons a prescriber specifies a compounded version include: a strength not commercially available (e.g., 5 mcg or 40 mcg per dose), a bi-mix or tri-mix combination (alprostadil combined with papaverine and/or phentolamine) for patients who need a multi-agent vasoactive protocol, or a reduced-preservative formulation to minimize injection-site discomfort.

Compounding pharmacies operating in New Jersey must hold an active NJ Board of Pharmacy license, comply with USP Chapter 797 standards for sterile preparations, and use only FDA-registered API suppliers [5]. They may ship compounded alprostadil to patients within New Jersey on a valid prescription. Shipping to patients in other states requires that the pharmacy also hold a non-resident pharmacy permit for the destination state.

The FDA's 2023 guidance on compounded drug products specifies that 503A pharmacies may not produce compounded versions of FDA-approved drugs in "essentially a copy" format without a documented clinical difference. A prescriber who orders compounded alprostadil 20 mcg intracavernosal injection, identical in every parameter to commercial Caverject 20 mcg, must document the clinical rationale for compounding in the prescription or accompanying letter [13].

When selecting a 503A pharmacy, confirm three things: active NJ Board of Pharmacy license, current USP 797 compliance certificate, and PCAB (Pharmacy Compounding Accreditation Board) accreditation. PCAB-accredited pharmacies undergo independent sterility and potency audits, which reduces the risk of subpotent or contaminated preparations [14].

Safety, side effects, and when to seek emergency care

Alprostadil's most common side effects are local: penile pain at the injection site occurs in 10 to 37% of patients using Caverject in clinical trials, and urethral burning occurs in 12% of MUSE users [2, 3]. Systemic hypotension severe enough to cause syncope occurs in fewer than 1% of patients at recommended doses.

Priapism, defined as an erection lasting more than four hours, is the most serious adverse event. The published incidence in clinical trials is 1 to 4% over the course of therapy, but the risk is highest with the first few doses before titration is optimized [3]. Any erection exceeding four hours requires an emergency department visit. The standard first-line treatment is aspiration of blood from the corpus cavernosum followed by intracavernosal injection of a sympathomimetic agent such as phenylephrine 100 mcg to 500 mcg; the AUA guideline specifies phenylephrine as the preferred agent due to its minimal cardiac beta-adrenergic activity [6].

Penile fibrosis (Peyronie's-like plaque at the injection site) occurs in 2 to 3% of patients with chronic use beyond twelve months [3]. Rotating the injection site and using the smallest effective dose reduces this risk. A 2019 study in the Journal of Sexual Medicine (N=312) confirmed that strict site-rotation protocols reduced fibrosis incidence to 1.1% at two years compared with 3.8% in men without a documented rotation schedule (P<0.05) [15].

Patients with sickle cell disease or trait, multiple myeloma, or leukemia carry a higher priapism risk and require dose reduction and closer monitoring. The FDA label contraindicates alprostadil in these populations unless the benefit clearly outweighs the risk [1].

Injection training and ongoing monitoring

The FDA-approved Caverject label and the AUA guideline both require that the first injection be performed or directly supervised by the prescribing clinician [1, 6]. This requirement applies to telehealth patients: if the initial consultation was via video, the provider must arrange an in-person injection training session before the patient self-administers at home. In New Jersey, this training can take place at the prescribing clinic, at a partnering urology practice, or at a nurse-run injection training clinic.

Follow-up appointments are recommended at four weeks and twelve weeks after the first self-administration. The provider assesses injection technique, dose adequacy, presence of nodules or pain, and partner satisfaction. Dose adjustments are made in increments of 2.5 mcg to 5 mcg (intracavernosal) or 125 mcg to 250 mcg (intraurethral) based on response and tolerability [6].

A 2020 meta-analysis in the International Journal of Impotence Research (11 studies, N=4,214) found that structured follow-up programs at four and twelve weeks produced a 22% higher rate of continued alprostadil use at one year compared with no structured follow-up (62% vs. 40% continuation rate, P<0.01) [16]. Consistent follow-up is therefore not a bureaucratic formality but a direct predictor of long-term treatment success.

Men combining alprostadil with a PDE5 inhibitor (a practice sometimes called "combination therapy") must do so only under physician supervision. The combination amplifies vasodilatory effects and meaningfully increases the risk of hypotension. The AUA does not currently endorse routine combination use outside a monitored clinical trial setting [6].

Transferring an existing prescription to New Jersey

If you hold a valid alprostadil prescription from another state and relocate to or spend extended time in New Jersey, you have two options. First, a New Jersey pharmacy may fill an out-of-state prescription for a non-controlled substance if the prescribing provider holds a valid license in their home state and the prescription meets NJ formatting requirements (prescriber's name, address, NPI, patient name, drug, dose, quantity, and date). Second, if the original prescriber is not licensed in NJ, you need a new prescription from an NJ-licensed provider.

Transferring a prescription between pharmacies within New Jersey follows standard practice: the receiving pharmacy contacts the dispensing pharmacy directly. For compounded alprostadil, the compounding pharmacy must be licensed in NJ; a prescription from a licensed NJ prescriber cannot be filled by an out-of-state 503A pharmacy unless that pharmacy holds a NJ non-resident pharmacy permit [5].

Bring documentation of your current dose, duration of therapy, and any prior authorization approval letters. A new NJ prescriber reviewing a transfer case does not need to repeat the full diagnostic workup if labs from within six months are available and the clinical history is clearly documented.